In a case series on pancreatic ductal adenocarcinoma, 8 out of 10 pancreatic cancer patients with ATM, ATR, or CHEK2 GPVs were treated with an oxaliplatin-based chemotherapy regimen and 5 patients demonstrated a partial response or stable disease [119]. This evidence concerns the gene ATR and pancreatic neoplasm.